Serum albumin improves recovery from spinal cord injury

Journal of Neuroscience Research

Volumn 85, Issue 7, 2007, Pages 1558-1567

  Cain, Lisa D ^a   Nie, Linghui ^a   Hughes, Michael G ^a   Johnson, Kathia ^a   Echetebu, Clement ^a   Xu, Guo Ying ^a   Hulsebosch, Claire E ^a   McAdoo, David J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Albumin; Neuroprotection; Spinal cord injury

Indexed keywords

ALBUMIN; GLUTAMIC ACID; NERVE GROWTH FACTOR; TYROSINE KINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SPINAL CORD INJURY; TREATMENT OUTCOME;

ANIMALS; CELLS, CULTURED; GLUTAMIC ACID; MALE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SERUM ALBUMIN; SPINAL CORD INJURIES;

EID: 34248232943     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21265     Document Type: Article

References (55)

1. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P. 1995. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15:961-973.
2. Atabay C, Cagnoli CM, Kharlamov E, Ikonomovic MD, Manev H. 1996. Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists. J Neurosci Res 43:465-475.
3. Basso DM, Beattie MS, Bresnahan JC. 1995. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12:1-21.
4. Beit-Yannai E, Trembovler V, Horowitz M, Lazarovici P, Kohen R, Shohami E. 1998. Neuroprotection against oxidative stress by serum from heat acclimated rats. Neurosci Lett 254:89-92.
5. Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, Ginsberg MD. 1999a. Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J Neurotrauma 16:445-453.
6. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. 1997. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 87:595-601.
7. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. 2001. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 32:553-560.
8. Belayev L, Saul I, Huh PW, Finotti N, Zhao W, Busto R, Ginsberg MD. 1999b. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res 845:107-111.
9. Bottenstein JE, Sato GH. 1979. Growth of a rat neuroblastoma cell line in serum-free supplemental medium. Proc Natl Acad Sci USA 76:514-517.
10. Bracken MB, Holford TR. 1993. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 79:500-507.
11. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. 1997. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277:1597-1604.
12. Cantin AM, Paquette B, Richter M, Larivee P. 2000. Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. Am J Respir Crit Care Med 162:1539-1546.
13. Carver FJ, Farb DL, Frieden E. 1982. The effect of albumin, ceruloplasmin, and other serum constituents on Fe(II) oxidation. Biol Trace Element Res 4:1-19.
14. Choi DW, Maulucci-Gedde M, Kriegstein AR. 1987. Glutamate neurotoxicity in cortical cell culture. J Neurosci 7:357-368.
15. Davidsohn I, Henry JB. 1974. Clinical diagnosis by laboratory methods. In: Davidsohn I, Henry JB, editors. Philadelphia: Saunders. p 1392.
16. Doppenberg EM, Bullock R. 1997. Clinical neuro-protection trials in severe traumatic brain injury: lessons from previous studies. J Neurotrauma 14:71-80.
17. Doppenberg EM, Choi SC, Bullock R. 1997. Clinical trials in traumatic brain injury. What can we learn from previous studies? Ann. N Y Acad Sci 825:305-322.
18. Dux E, Oschlies U, Wiessner C, Hossmann KA. 1992. Glutamate-induced ribosomal disaggregation and ultrastructural changes in rat cortical neuronal culture: protective effect of horse serum. Neurosci Lett 141:173-176.
19. Emerson TE Jr. 1989. Unique features of albumin: a brief review. Crit Care Med 17:690-694.
20. Faden AI, Demediuk P, Panter SS, Vink R. 1989. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244:798-800.
21. Faden AI, Ellison JA, Noble LJ. 1990. Effects of competitive and noncompetitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 175:165-174.
22. Faden AI, Lemke M, Simon RP, Noble LJ. 1988. N-methyl-D-aspartate antagonist MK801 improves outcome following traumatic spinal cord injury in rats: behavioral, anatomic, and neurochemical studies. J Neurotrauma 5:33-45.
23. Faden AI, Simon RP. 1988. A potential role for excitotoxins in the pathophysiology of spinal cord injury. Ann Neurol 23:623-626.
24. Gum ET, Swanson RA, Alano C, Liu J, Hong S, Weinstein PR, Panter SS. 2004. Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke 35:590-595.
25. Halliwell B. 1988. Albumin - an important extracellular antioxidant? Biochem Pharmacol 37:569-571.
26. Huang PP, Young W. 1994. The effects of arterial blood gas values on lesion volumes in a graded rat spinal cord contusion model. J Neurotrauma 11:547-562.
27. Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. 1998. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res 804:105-113.
28. Hulsebosch CE, Xu GY, Perez-Polo JR, Westlund KN, Taylor CP, McAdoo DJ. 2000. Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. J Neurotrauma 17:1205-1217.
29. Hurlbert RJ. 2000. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 93:1-7.
30. Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. 1999. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 277:F711-F722.
31. Isahara K, Ohsawa Y, Kanamori S, Shibata M, Waguri S, Sato N, Gotow T, Watanabe T, Momoi T, Urase K, Kominami E, Uchiyama Y. 1999. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neuroscience 91:233-249.
32. Liu D, Thangnipon W, McAdoo DJ. 1991. Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res 547:344-348.
33. Liu D, Xu GY, Pan E, McAdoo DJ. 1999. Neurotoxicity of glutamate at the concentration released upon spinal cord injury. Neuroscience 93:1383-1389.
34. Mattson MP, Lovell MA, Furukawa K, Markesbery WR. 1995. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 65:1740-1751.
35. Mills CD, Grady JJ, Hulsebosch CE. 2001. Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. J Neurotrauma 18:1091-1105.
36. Mills CD, Johnson KM, Hulsebosch CE. 2002. Group I metabotropic glutamate receptors in spinal cord injury: roles in neuroprotection and the development of chronic central pain. J Neurotrauma 19:23-42.
37. Narayan RK, Michel ME, Ansell B, Baethmann A, Biegon A, Bracken MB, Bullock MR, Choi SC, Clifton GL, Contant CF, Coplin WM, Dietrich WD, Ghajar J, Grady SM, Grossman RG, Hall ED, Heetderks W, Hovda DA, Jallo J, Katz RL, Knoller N, Kochanek PM, Maas AI, Majde J, Marion DW, Marmarou A, Marshall LF, McIntosh TK, Miller E, Mohberg N, Muizelaar JP, Pitts LH, Quinn P, Riesenfeld G, Robertson CS, Strauss KI, Teasdale G, Temkin N, Tuma R, Wade C, Walker MD, Weinnch M, Whyte J, Wilberger J, Young AB, Yurkewicz L. 2002. Clinical trials in head injury. J Neurotrauma 19:503-557.
38. Nellgard B, Wieloch T. 1992. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia. J Cereb Blood Flow Metab 12:2-11.
39. Olney JW, Farber NB. 1995. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-345.
40. Peters TP Jr. 1985. Serum albumin. Adv Protein Chem 37:161-245.
41. Ratan RR, Lee PJ, Baraban JM. 1996. Serum deprivation inhibits glutathione depletion-induced death in embryonic cortical neurons: evidence against oxidative stress as a final common mediator of neuronal apoptosis. Neurochem Int 29:153-157.
42. Rende M, Brizi E, Conner J, Treves S, Censier K, Provenzano C, Taglialatela G, Sanna PP, Donato R. 2000. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA. Ind J Dev Neurosci 18:869-885.
43. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. 2000. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 86:E50-E54.
44. Scheff SW, Rabchevsky AG, Fugaccia I, Main JA, Lumpp JE Jr. 2003. Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J Neurotrauma 20:179-193.
45. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T. 1990. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: a neuroprotectant for cerebral ischemia. Science 247:571-574.
46. Spieker-Polet H, Polet H. 1976. Identification of albumin as the serum factor essential for the growth of activated human lymphocytes. J Biol Chem 251:987-992.
47. Tullis JL. 1977. Albumin. 2. Guidelines for clinical use. JAMA 237:460-463.
48. Uto A, Dux E, Hossmann KA. 1994. Effect of serum on intracellular calcium homeostasis and survival of primary cortical and hippocampal CA1 neurons following brief glutamate treatment. Metab Brain Dis 9:333-345.
49. Wasil M, Halliwell B, Hutchison DC, Baum H. 1987. The antioxidant action of human extracellular fluids. Effect of human serum and its protein components on the inactivation of alpha 1-antiproteinase by hypochlorous acid and by hydrogen peroxide. Biochem J 243:219-223.
50. Wayner DD, Burton GW, Ingold KU, Locke S. 1985. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett 187:33-37.
51. Wood AM, Tiwari P, Bristow DR. 1997. Media composition modulates excitatory amino acid-induced death of rat cerebellar granule cells. Hum Exp Toxicol 16:350-355.
52. Wrathall JR, Choiniere D, Teng YD. 1994. Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX. J Neurosci 14:6598-6607.
53. Xu GY, Hughes MG, Ye YZ, Hulsebosch CE, McAdoo DJ. 2004. Concentration of glutamate released following spinal cord injury kill oligodendrocytes in the spinal cord. Exp Neurol 187:329-336.
54. Xu G-Y, Hughes MG, Zhang L, Cain L, McAdoo DJ. 2005. Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments. Neurosci Lett 384:271-276.
55. Yanase M, Sakou T, Fukuda T. 1995. Role of N-methyl-D-aspartate receptor in acute spinal cord injury. J Neurosurg 83:884-888.